What is William Blair’s Estimate for ZVRA FY2026 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – William Blair issued their FY2026 earnings per share estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst S. Corwin forecasts that the company will post earnings of $0.54 per share for the year. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The company had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. During the same period in the prior year, the business posted ($0.15) EPS.

Several other research analysts have also weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday. JMP Securities started coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Monday, September 30th. Finally, Guggenheim initiated coverage on Zevra Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $20.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $21.00.

Zevra Therapeutics Trading Up 4.3 %

Shares of NASDAQ ZVRA opened at $9.03 on Friday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. Zevra Therapeutics has a one year low of $4.18 and a one year high of $9.21. The business has a 50-day moving average price of $7.97 and a two-hundred day moving average price of $6.44. The firm has a market capitalization of $475.14 million, a PE ratio of -4.58 and a beta of 1.93.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC lifted its stake in Zevra Therapeutics by 8.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after acquiring an additional 1,717 shares in the last quarter. City State Bank lifted its position in shares of Zevra Therapeutics by 14.1% in the third quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after purchasing an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares during the last quarter. International Assets Investment Management LLC grew its position in Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares in the last quarter. Finally, IFG Advisors LLC increased its stake in Zevra Therapeutics by 41.2% in the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock valued at $183,000 after buying an additional 7,700 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.